A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the Eastern Cooperative Oncology Group (E1500) Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Sirolimus

abstract

  • Temsirolimus (CCI 779), given at 25 or 250 mg weekly, seemed not to increase the PFS in this patient population.

publication date

  • January 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e318155a439

PubMed ID

  • 17975496

Additional Document Info

start page

  • 1036

end page

  • 41

volume

  • 2

number

  • 11